BioNTech has patented a method to screen for a genotype associated with loss of antigen presentation via MHC class I, crucial for immunotherapy effectiveness. The method involves identifying specific chromosomal events in a human subject’s DNA sample to determine resistance to treatments like vaccination. GlobalData’s report on BioNTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioNTech, Personalized cancer vaccines was a key innovation area identified from patents. BioNTech's grant share as of February 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Screening for genotype loss of antigen presentation via mhc class i
A recently granted patent (Publication Number: US11920194B2) discloses a method for screening for a genotype associated with the loss of antigen presentation via major histocompatibility complex (MHC) class I. The method involves obtaining a sample containing nucleic acid from a human subject and identifying a chromosomal deletion and inversion event in chromosome 15, leading to the loss of the beta-2-microglobulin (B2M) locus. This identification is achieved through specific amplification of nucleic acid sequences and detection of hybridization with probes, indicating the presence of the genotype for loss of antigen presentation via MHC class I.
Furthermore, the patent details the specific sequences and primers used in the amplification process to detect the chromosomal deletion and inversion event accurately. The method's application extends to predicting resistance against immunotherapy, particularly tumor immunotherapy, based on the identified genotype. By targeting the loss of antigen presentation via MHC class I, the method provides a valuable tool for personalized medicine and treatment strategies, offering insights into potential immunotherapeutic outcomes based on the genetic profile of the individual. The patent emphasizes the importance of precise genetic screening in determining the efficacy of immunotherapy and highlights the role of chromosomal events in influencing antigen presentation mechanisms.
To know more about GlobalData’s detailed insights on BioNTech, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
